Spero Therapeutics (SPRO) Non-Current Debt (2019 - 2026)

Spero Therapeutics (SPRO) has reported Non-Current Debt for 8 consecutive years, with $91000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Debt changed N/A year-over-year to $91000.0; the trailing twelve-month figure through Jun 2026 stood at $91000.0 (changed N/A YoY), and the FY2025 full-year result was $91000.0, changed N/A from the prior year.
• Non-Current Debt held at $91000.0 in Q2 2026 per SPRO's latest filing, from $91000.0 in the prior quarter.
• Across five years, Non-Current Debt topped out at $128000.0 in Q1 2022 and bottomed at $13000.0 in Q3 2024.
• Historically, Non-Current Debt has averaged $78785.7 across 5 years, with a median of $89000.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Non-Current Debt retreated 9.38% in 2023, then plunged 79.03% in 2024.
• Over 5 years, Non-Current Debt stood at $96000.0 in 2022, then declined by 9.38% to $87000.0 in 2023, then slumped by 85.06% to $13000.0 in 2024, then jumped by 600.0% to $91000.0 in 2025, then changed by 0.0% to $91000.0 in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $91000.0, $91000.0, and $91000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.